ImmPACT Bio USA INC
8501 Fallbrook Avenue
West Hills
California
91304
United States
24 articles about ImmPACT Bio USA INC
-
ImmPACT Bio Recognized in BioSpace's 2024 Best Places to Work
11/8/2023
ImmPACT Bio USA , Inc. today announced it has been named on the BioSpace 2024 Best Places to Work small employer list.
-
ImmPACT Bio Appoints Han Lee, Ph.D., MBA, as President and Chief Financial Officer
10/31/2023
ImmPACT Bio USA, Inc., a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor T-cell therapies for treating cancer and autoimmune diseases, announced the appointment of Han Lee, Ph.D., MBA, as president and chief financial officer.
-
ImmPACT Bio to Participate in the 2023 Truist Securities BioPharma Symposium
10/30/2023
ImmPACT Bio USA , Inc. today announced that it will participate in the 2023 Truist Securities BioPharma Symposium, to be held from November 8-9, 2023.
-
ImmPACT Bio to Present at the BIO Investor Forum
10/11/2023
ImmPACT Bio USA , Inc. today announced that it will participate at the BIO Investor Forum, to be held from October 17-18, 2023 in San Francisco, CA.
-
ImmPACT Bio Granted FDA Fast Track Designation for IMPT-514 for the Treatment of Both Active, Refractory Lupus Nephritis and Systemic Lupus Erythematosus
10/10/2023
ImmPACT Bio USA , Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for IMPT-514, a potential first-in-class CD19/CD20 CAR-T therapy for the treatment of patients with active refractory lupus nephritis (LN) and systemic lupus erythematosus (SLE).
-
ImmPACT Bio to Present at Cell & Gene Meeting on the Mesa
10/3/2023
ImmPACT Bio USA , Inc. ("ImmPACT BIO"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced that it will participate at the 2023 Cell & Gene Meeting on the Mesa, being held October 10-12, 2023.
-
ImmPACT Bio Doses First Patient in Phase 1/2 Trial Evaluating IMPT-314, a Bispecific CD19/CD20 CAR T-cell Therapy for the Treatment of Aggressive B-cell Lymphoma
9/19/2023
ImmPACT Bio USA, Inc. announced that the first patient has been dosed in the Phase 1/2 trial evaluating IMPT-314, a bispecific CD19/CD20 CAR T-cell therapy for the treatment of relapsed or refractory (R/R) aggressive B-cell lymphoma.
-
ImmPACT Bio to Present at Jefferies Cell & Genetic Medicine Summit
9/13/2023
ImmPACT Bio USA , Inc. today announced that it will participate at the Jefferies Cell & Genetic Medicine Summit, to be held from September 26 -27, 2023.
-
ImmPACT Bio Announces FDA Clearance of IND Application for Bispecific CD19/CD20 CAR T Therapy IMPT-514 for the Treatment of Refractory Systemic Lupus Erythematosus
8/15/2023
ImmPACT Bio USA, Inc. today announced the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for IMPT-514, a bispecific CD19/CD20 CAR T therapy for the treatment of active, refractory systemic lupus erythematosus (SLE).
-
ImmPACT Bio to Present at the 2023 Jefferies Healthcare Conference
5/23/2023
ImmPACT Bio USA, Inc. today announced that it will participate at the 2023 Jefferies Healthcare Conference, to be held from June 7-9, 2023, in New York.
-
ImmPACT Bio Granted FDA Fast Track Designation for IMPT-314 in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma
5/15/2023
ImmPACT Bio USA, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for IMPT-314, a potential first-in-class CD19/CD20 CAR T therapy for the treatment of patients with B-cell mediated malignancies.
-
ImmPACT Bio to Present at the 2023 RBC Capital Markets Global Healthcare Conference
5/10/2023
ImmPACT Bio USA , Inc. today announced that it will participate at the 2023 RBC Capital Markets Global Healthcare Conference, to be held from May 16-17, 2023.
-
ImmPACT Bio Appoints Biren Amin, M.B.A. to its Board of Directors
2/8/2023
ImmPACT Bio USA , Inc. today announced the appointment of Biren Amin, M.B.A., to its board of directors.
-
ImmPACT Bio Announces FDA Clearance of IND for Novel Bispecific CAR to Treat Aggressive B-cell Lymphoma
1/24/2023
ImmPACT Bio USA, Inc. today announced clearance of its first Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for IMPT-314, a bispecific "OR-Gate" autologous CAR T-cell therapy targeting the B-cell antigens CD19 and CD20. IMPT-314 will be studied in a Phase 1/2 clinical trial in patients with aggressive B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL).
-
Biopharma and life science companies added changes to their leadership teams this week, with Cara Therapeutics, SOTIO Biotech, Agenus, and more filling several C-suite positions.
-
ImmPACT Bio Names Jonathan Benjamin, M.D., Ph.D. as Chief Medical Officer
9/13/2022
ImmPACT Bio USA , Inc. today announced the appointment of Jonathan Benjamin, M.D., Ph.D. as its chief medical officer.
-
ImmPACT Bio Names Vikram Lamba as Chief Financial Officer and Head of Business Development
8/9/2022
ImmPACT Bio USA , Inc. today announced the appointment of Vikram Lamba, M.B.M. as chief financial officer (CFO) and head of business development.
-
ImmPACT Bio Names Sylvain Roy as Chief Technology Officer
5/10/2022
ImmPACT Bio USA , Inc. today announced the appointment of Sylvain Roy as chief technology officer.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
ImmPACT Bio Names Venkat Yepuri as Chief Operating Officer
4/19/2022
ImmPACT Bio USA , Inc. today announced the appointment of Venkata (Venkat) P. Yepuri as chief operating officer.